Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin.


Journal

BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768

Informations de publication

Date de publication:
15 Apr 2019
Historique:
received: 05 03 2019
accepted: 06 04 2019
entrez: 18 4 2019
pubmed: 18 4 2019
medline: 14 8 2019
Statut: epublish

Résumé

Intravenous immune globulin (IVIG), pooled from human blood, is a polyspecific antibody preparation that inhibits the super-antigenic proteins associated with streptococcal and staphylococcal toxic shock, and the Shiga toxin. In addition to this toxin-neutralising activity, IVIG contains other pathogen-reactive antibodies that may confer additional therapeutic benefits. We sought to determine if pathogen-reactive antibodies that promote opsonophagocytosis of different organisms can be sequentially affinity-purified from one IVIG preparation. Antibodies that recognise cell wall antigens of Streptococcus pyogenes, Staphylococcus aureus, and vancomycin-resistant enterococcus (VRE) were sequentially affinity-purified from a single preparation of commercial IVIG and opsonophagocytic activity was assessed using a flow cytometry assay of neutrophil uptake. Non-specific IgG-binding proteins were removed from the S. aureus preparations using an immobilised Fc fragment column, produced using IVIG cleaved with the Immunoglobulin G-degrading enzyme of S. pyogenes (IdeS). Affinity-purified anti-S. aureus and anti-VRE immunoglobulin promoted significantly higher levels of opsonophagocytic uptake by human neutrophils than IVIG when identical total antibody concentrations were compared, confirming activity previously shown for affinity-purified anti-S. pyogenes immunoglobulin. The opsonophagocytic activities of anti-S. pyogenes, anti-S. aureus, and anti-VRE antibodies that were sequentially purified from a single IVIG preparation were undiminished compared to antibodies purified from previously unused IVIG.

Identifiants

pubmed: 30992057
doi: 10.1186/s13104-019-4262-8
pii: 10.1186/s13104-019-4262-8
pmc: PMC6466806
doi:

Substances chimiques

Antibodies, Bacterial 0
Antigens, Bacterial 0
Immunoglobulin Fc Fragments 0
Immunoglobulins, Intravenous 0
Opsonin Proteins 0

Types de publication

Journal Article

Langues

eng

Pagination

228

Subventions

Organisme : National Institute for Health Research
ID : HPRU-2012-10047
Organisme : Medical Research Council
ID : G0800777
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_12015
Pays : United Kingdom
Organisme : Medical Research Council
ID : Confidence in Concept
Pays : United Kingdom
Organisme : United Kingdom Clinical Research Collaboration
ID : G0800777

Références

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7687-92
pubmed: 12032344
Clin Diagn Lab Immunol. 2004 Nov;11(6):1158-64
pubmed: 15539522
Antimicrob Agents Chemother. 2007 Dec;51(12):4249-54
pubmed: 17893153
Autoimmun Rev. 2008 Jun;7(6):435-9
pubmed: 18558358
Curr Opin Pharmacol. 2009 Oct;9(5):552-7
pubmed: 19733119
Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1149-60
pubmed: 23532569
Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090
pubmed: 24043371
Clin Microbiol Infect. 2014 May;20 Suppl 5:66-75
pubmed: 24476315
Infection. 2015 Apr;43(2):169-75
pubmed: 25428225
Sci Rep. 2015 Oct 28;5:15825
pubmed: 26508447
J Microbiol Methods. 2016 May;124:69-71
pubmed: 27030640
Sci Transl Med. 2016 Sep 21;8(357):357ra124
pubmed: 27655850
Infect Drug Resist. 2016 Dec 08;9:301-311
pubmed: 27994476
Microb Genom. 2016 Feb 23;2(2):e000049
pubmed: 28348843
J Pediatr. 1988 Dec;113(6):1008-14
pubmed: 3057156
Infect Immun. 1996 May;64(5):1659-65
pubmed: 8613375
Microbiology. 1998 Apr;144 ( Pt 4):985-91
pubmed: 9579072

Auteurs

Mark Reglinski (M)

Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.

Shiranee Sriskandan (S)

Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK. s.sriskandan@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH